The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy

Research in Microbiology

Volumn 166, Issue 4, 2015, Pages 244-254

  Kubiak, Aleksandra M ^a   Minton, Nigel P ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cancer therapy; Clostridia; Hypoxia; Prodrug; Prodrug converting enzyme; Spores

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL ENZYME; COMBRETASTATIN A4; CYTOSINE DEAMINASE; DIHYDROPTERIDINE REDUCTASE; DOLASTATIN 10; DOXORUBICIN; ENZYME; ESCHERICHIA COLI PROTEIN; FLUCYTOSINE; FLUOROURACIL; LIPOSOME; NITROREDUCTASE; PRODRUG; PRODRUG CONVERTING ENZYME; SN 24927; TRETAZICAR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DRUG CARRIER;

BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL SPORE; BACTERIAL STRAIN; BRACHYTHERAPY; CANCER THERAPY; CHEMICAL EXCHANGE SATURATION TRANSFER; CLOSTRIDIA; CLOSTRIDIUM ACETOBUTYLICUM; CLOSTRIDIUM BEIJERINCKII; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM DIRECTED ANTIBODY THERAPY; CLOSTRIDIUM HISTOLYTICUM; CLOSTRIDIUM NOVYI; CLOSTRIDIUM ONCOLYTICUM; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM SPOROGENES; CLOSTRIDIUM TETANI; CODON USAGE; COLONY FORMING UNIT; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENZYME PRODRUG THERAPY; ESCHERICHIA COLI; HORIZONTAL GENE TRANSFER; HUMAN; HYPERSENSITIVITY; HYPOXIA; INTOXICATION; LIVER TOXICITY; MICROARRAY ANALYSIS; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECIES; TUMOR CELL DESTRUCTION; ANAEROBIC GROWTH; ANIMAL; BIOLOGICAL THERAPY; CLOSTRIDIUM; GENETICS; MEDICAL RESEARCH; NEOPLASMS; PROCEDURES; TRENDS;

CLOSTRIDIA; CLOSTRIDIUM;

ANAEROBIOSIS; ANIMALS; BIOLOGICAL THERAPY; BIOMEDICAL RESEARCH; CLOSTRIDIUM; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; SPORES, BACTERIAL;

EID: 84928554535     PISSN: 09232508     EISSN: 17697123     Source Type: Journal    
DOI: 10.1016/j.resmic.2014.12.006     Document Type: Review

References (86)

1. Macdonald F. Molecular biology of cancer 2004, BIOS Scientific Publ.
2. Weinberg R.A. The biology of cancer 2007, Garland Science, New York.
3. Iwamoto T. Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol Pharm Bull 2013, 36:715-718.
4. Weatherall D.J. Scope and limitations of gene therapy. Br Med Bull 1995, 51:1-11.
5. Somia N., Wang L., Gage F. Gene therapy: promises, problems and prospects. Genes Resist Dis 2000, 147.
6. Mountain A. Gene therapy: the first decade. Trends Biotechnol 2000, 18:119-128.
7. Stem Cell Network, Cancer: solid tumor, [accessed 12/2014]. http://www.stemcellnetwork.ca/index.php?page=cancers-solid-tumor.
8. Brown J.M. Tumor hypoxia in cancer therapy. Methods Enzym 2007, 435:297-321.
9. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276.
10. Weinmann M., Belka C., Plasswilm L. Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours. Onkologie 2004, 27:83-90.
11. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer metastasis Rev 2007, 26:225-239.
12. Nordsmark M., Bentzen S.M., Rudat V., Brizel D., Lartigau E., Stadler P., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol: J Eur Soc Ther Radiol Oncol 2005, 77:18-24.
13. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996, 56:941-943.
14. Hockel M., Knoop C., Schlenger K., Vorndran B., Baussmann E., Mitze M., et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol: J Eur Soc Ther Radiol Oncol 1993, 26:45-50.
15. Bennewith K.L., Dedhar S. Targeting hypoxic tumour cells to overcome metastasis. BMC cancer 2011, 11:504.
16. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904.
17. Duffy J.P., Eibl G., Reber H.A., Hines O.J. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol cancer 2003, 2:12.
18. Wells C.L., Wilkins T.D. Clostridia: sporeforming anaerobic Bacilli. Medical microbiology 1996, Galveston (TX). S. Baron (Ed.).
19. Marth E., Ascher W.P., Pavelka R., Mose J.R. Tumor lysis of a glioblastoma by Clostridium oncolyticum. J Chemother 1989, 1:1177-1178.
20. Lambin P., Theys J., Landuyt W., Rijken P., van der Kogel A., van der Schueren E., et al. Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe 1998, 4:183-188.
21. Theys J., Landuyt A.W., Nuyts S., Van Mellaert L., Lambin P., Anne J. Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer Detect Prev 2001, 25:548-557.
22. Van Mellaert L., Barbe S., Anne J. Clostridium spores as anti-tumour agents. Trends Microbiol 2006, 14:190-196.
23. Mengesha A., Dubois L., Chiu R.K., Paesmans K., Wouters B.G., Lambin P., et al. Potential and limitations of bacterial-mediated cancer therapy. Front Biosci: J Virtual Libr 2007, 12:3880-3891.
24. St Jean A.T., Zhang M., Forbes N.S. Bacterial therapies: completing the cancer treatment toolbox. Curr Opin Biotechnol 2008, 19:511-517.
25. Wei M.Q., Mengesha A., Good D., Anne J. Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett 2008, 259:16-27.
26. Zu C., Wang J. Tumor-colonizing bacteria: a potential tumor targeting therapy. Crit Rev Microbiol 2014, 40:225-235.
27. Moese J.R., Moese G. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res 1964, 24:212-216.
28. Thiele E.H., Arison R.N., Boxer G.E. Oncolysis by clostridia. Iv. Effect of nonpathogenic clostridial spores in normal and pathological tissues. Cancer Res 1964, 24:234-238.
29. Thiele E.H., Arison R.N., Boxer G.E. Oncolysis by clostridia. Iii. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res 1964, 24:222-233.
30. Lemmon M.J., van Zijl P., Fox M.E., Mauchline M.L., Giaccia A.J., Minton N.P., et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther 1997, 4:791-796.
31. Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Järvinen T., et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008, 7:255-270.
32. Stella V., Borchardt R., Hageman M., Oliyai R., Maag H., Tilley J. Prodrugs: challenges and rewards 2007, Springer.
33. Cobb L., Connors T., Elson L., Khan A., Mitchley B., Ross W., et al. 2, 4-Dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem Pharmacol 1969, 18:1519-1527.
34. Knox R.J., Friedlos F., Biggs P.J., Flitter W.D., Gaskell M., Goddard P., et al. Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954. Biochem Pharmacol 1993, 46:797-803.
35. Knox R.J., Friedlos F., Sherwood R.F., Melton R.G., Anlezark G.M. The bioactivation of 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954)-II: a comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem Pharmacol 1992, 44:2297-2301.
36. Anlezark G.M., Vaughan T., Fashola-Stone E., Michael N.P., Murdoch H., Sims M.A., et al. Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954. Microbiology 2002, 148:297-306.
37. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4:437-447.
38. Theys J., Pennington O., Dubois L., Anlezark G., Vaughan T., Mengesha A., et al. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects invivo. Br J cancer 2006, 95:1212-1219.
39. Minton N.P. Clostridia in cancer therapy. Nat Rev Microbiol 2003, 1:237-242.
40. Minton N.P., Mauchline M.L., Lemmon M.J., Brehm J.K., Fox M., Michael N.P., et al. Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiol Rev 2006, 17:357-364.
41. Workman P., White R.A., Talbot K. CB 1954 revisited. I. Disposition kinetics and metabolism. Cancer Chemother Pharmacol 1986, 16:1-8.
42. Workman P., Morgan J.E., Talbot K., Wright K.A., Donaldson J., Twentyman P.R. CB 1954 revisited. II. Toxicity and antitumour activity. Cancer Chemother Pharmacol 1986, 16:9-14.
43. Knox R.J., Friedlos F., Jarman M., Roberts J.J. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol 1988, 37:4661-4669.
44. Chung-Faye G., Palmer D., Anderson D., Clark J., Downes M., Baddeley J., et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin cancer Res: Off J Am Assoc Cancer Res 2001, 7:2662-2668.
45. Tang M.H., Helsby N.A., Wilson W.R., Tingle M.D. Aerobic 2- and 4-nitroreduction of CB 1954 by human liver. Toxicology 2005, 216:129-139.
46. Liu S.C., Ahn G.O., Kioi M., Dorie M.J., Patterson A.V., Brown J.M. Optimized Clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. Cancer Res 2008, 68:7995-8003.
47. Patterson A.V., Ferry D.M., Edmunds S.J., Gu Y., Singleton R.S., Patel K., et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin cancer Res: Off J Am Assoc Cancer Res 2007, 13:3922-3932.
48. Guise C.P., Abbattista M.R., Singleton R.S., Holford S.D., Connolly J., Dachs G.U., et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 2010, 70:1573-1584.
49. McKeage M.J., Jameson M.B., Ramanathan R.K., Rajendran J., Gu Y., Wilson W.R., et al. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. BMC cancer 2012, 12:496.
50. Singleton D.C., Li D., Bai S.Y., Syddall S.P., Smaill J.B., Shen Y., et al. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). Cancer gene Ther 2007, 14:953-967.
51. Grove J.I., Lovering A.L., Guise C., Race P.R., Wrighton C.J., White S.A., et al. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Res 2003, 63:5532-5537.
52. Race P.R., Lovering A.L., White S.A., Grove J.I., Searle P.F., Wrighton C.W., et al. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954. J Mol Biol 2007, 368:481-492.
53. Heap J.T. Novel prodrug converting enzymes and a direct DNA integration method for Clostridia 2007, PhD thesis, Nottingham University.
54. Emptage C.D., Knox R.J., Danson M.J., Hough D.W. Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation. Biochem Pharmacol 2009, 77:21-29.
55. Theys J., Landuyt W., Nuyts S., Van Mellaert L., van Oosterom A., Lambin P., et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther 2001, 8:294-297.
56. Heap J.T., Ehsaan M., Cooksley C.M., Ng Y.K., Cartman S.T., Winzer K., et al. Integration of DNA into bacterial chromosomes from plasmids without a counter-selection marker. Nucleic Acids Res 2012, 40:e59.
57. Heap J.T., Theys J., Ehsaan M., Kubiak A.M., Dubois L., Paesmans K., et al. Spores of Clostridium engineered for clinical efficacy and safety causeregression and cure of tumors invivo. Oncotarget 2014, 5(7):1761-1769.
58. Dang L.H., Bettegowda C., Huso D.L., Kinzler K.W., Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 2001, 98:15155-15160.
59. Dang L.H., Bettegowda C., Agrawal N., Cheong I., Huso D., Frost P., et al. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 2004, 3:326-337.
60. Smith A.B., Freeze B.S., LaMarche M.J., Sager J., Kinzler K.W., Vogelstein B. Discodermolide analogues as the chemical component of combination bacteriolytic therapy. Bioorg Med Chem Lett 2005, 15:3623-3626.
61. Bettegowda C., Dang L.H., Abrams R., Huso D.L., Dillehay L., Cheong I., et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A 2003, 100:15083-15088.
62. Cheong I., Huang X., Bettegowda C., Diaz L.A., Kinzler K.W., Zhou S., et al. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 2006, 314:1308-1311.
63. Groot A.J., Mengesha A., van der Wall E., van Diest P.J., Theys J., Vooijs M. Functional antibodies produced by oncolytic clostridia. Biochem Biophys Res Commun 2007, 364:985-989.
64. Krick E.L., Sorenmo K.U., Rankin S.C., Cheong I., Kobrin B., Thornton K., et al. Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors. Am J Vet Res 2012, 73:112-118.
65. Roberts N.J., Zhang L., Janku F., Collins A., Bai R.Y., Staedtke V., et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med 2014, 6. 249ra111.
66. Li Z., Fallon J., Mandeli J., Wetmur J., Woo S.L. A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Natl Cancer Inst 2008, 100:1389-1400.
67. Maeda T., Murata M., Chiba H., Takasawa A., Tanaka S., Kojima T., et al. Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer. Prostate 2012, 72:351-360.
68. Walther W., Petkov S., Kuvardina O.N., Aumann J., Kobelt D., Fichtner I., et al. Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors. Gene Ther 2012, 19:494-503.
69. Kominsky S.L., Vali M., Korz D., Gabig T.G., Weitzman S.A., Argani P., et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 2004, 164:1627-1633.
70. Michl P., Buchholz M., Rolke M., Kunsch S., Lohr M., McClane B., et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001, 121:678-684.
71. English D.P., Santin A.D. Claudins overexpression in ovarian Cancer: potential targets for Clostridium perfringens enterotoxin (CPE) based diagnosis and therapy. Int J Mol Sci 2013, 14:10412-10437.
72. Sarker M.R., Carman R.J., McClane B.A. Inactivation of the gene (cpe) encoding Clostridium perfringens enterotoxin eliminates the ability of two cpe-positive C. perfringens type A human gastrointestinal disease isolates to affect rabbit ileal loops. Mol Microbiol 1999, 33:946-958.
73. Heikinheimo A., Lindstrom M., Granum P.E., Korkeala H. Humans as reservoir for enterotoxin gene-carrying Clostridium perfringens type A. Emerg Infect Dis 2006, 12:1724-1729.
74. Theys J., Nuyts S., Landuyt W., Van Mellaert L., Dillen C., Bohringer M., et al. Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha. Appl Environ Microbiol 1999, 65:4295-4300.
75. Barbe S., Van Mellaert L., Theys J., Geukens N., Lammertyn E., Lambin P., et al. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol Lett 2005, 246:67-73.
76. Hutchens M., Luker G.D. Applications of bioluminescence imaging to the study of infectious diseases. Cell Microbiol 2007, 9:2315-2322.
77. Min J.J., Nguyen V.H., Kim H.J., Hong Y., Choy H.E. Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals. Nat Protoc 2008, 3:629-636.
78. Hope-Roberts M., Wainwright M., Horobin R.W. Real-time imaging of bacteria in living mice using a fluorescent dye. Biotech Histochem: Off Publ Biol Stain Comm 2011, 86:104-107.
79. Yu Y.A., Shabahang S., Timiryasova T.M., Zhang Q., Beltz R., Gentschev I., et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004, 22:313-320.
80. Scholz K.E., Kopka B., Wirtz A., Pohl M., Jaeger K.-E., Krauss U. Fusion of a flavin-based fluorescent protein to hydroxynitrile lyase from Arabidopsis thaliana improves enzyme stability. Appl Environ Microbiol 2013, 79:4727-4733.
81. Liu G., Bettegowda C., Qiao Y., Staedtke V., Chan K.W., Bai R., et al. Noninvasive imaging of infection after treatment with tumor-homing bacteria using chemical exchange saturation transfer (CEST) MRI. Magn Reson Med: Off J Soc Magnetic Reson Med Soc Magn Reson Med 2013, 70:1690-1698.
82. Barbe S., Van Mellaert L., Anne J. The use of clostridial spores for cancer treatment. J Appl Microbiol 2006, 101:571-578.
83. Baban C.K., Cronin M., O'Hanlon D., O'Sullivan G.C., Tangney M. Bacteriaas vectors for gene therapy of cancer. Bioeng Bugs 2010, 1:385-394.
84. Connell H.C. The study and treatment of cancer by proteolytic enzymes: preliminary report. Can Med Assoc J 1935, 33:364-370.
85. Parker R.C., Plummer H.C., Siebenmann C.O., Chapman M.G. Effect of histolyticus infection and toxin on transplantable mouse tumors. Proceedings of the society for experimental biology and medicine. Society for experimental biology and medicine (New York, NY), Royal Society of Medicine 1947, 461-467.
86. Malmgren R.A., Flanigan C.C. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 1955, 15:473-478.